Pharming Group N.V. (ETR:PHGN)

Market Cap	911.93M +59.6%
Revenue (ttm)	308.77M +26.8%
Net Income	325.58K
EPS	0.00
Shares Out	n/a
PE Ratio	2,800.95
Forward PE	34.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Average Volume	16,810
Open	1.330
Previous Close	1.323
Day's Range	1.327 - 1.330
52-Week Range	1.103 - 1.780
Beta	n/a
RSI	35.77
Earnings Date	Mar 12, 2026

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1988
• Employees: 404
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: PHGN

Financial Performance

In 2024, Pharming Group's revenue was $297.20 million, an increase of 21.15% compared to the previous year's $245.32 million. Losses were -$11.84 million, 12.3% more than in 2023.

Financial numbers in USD